Videos

A discussion on a novel therapeutic target for treatment, known as exportin 1 (XPO1), and the first selective nuclear export inhibitor to enter clinical use for patients who have developed relapse after IMiD and protease inhibitor therapies.

Jared Weiss, MD, discusses the pooled analysis of 3 phase 2 trials looking at trilaciclib in patients with extensive-stage small cell lung cancer.

An expert oncologist presents the case of a 69-year-old woman with advanced renal cell carcinoma, and considers available treatment options for patients with a similar disease setting.

Irene Ghobrial, MD, discusses the importance of the data made available through the Multiple Myeloma Research Foundation’s CureCloud research study.

David Reardon, MD, discusses the interim results and toxicity with INO-5401 and INO-9012 delivered intramuscularly with electroporation in combination with cemiplimab in patients with newly diagnosed glioblastoma.

Lori A. Leslie, MD, discusses options for patients with relapsed/refractory mantle cell lymphoma.

Terry P. Mamounas, MD, MPH, discusses the use of extended adjuvant therapy for patients with breast cancer and how the landscape is evolving.

Christian U. Blank, MD, PhD, discusses the most recent data from the phase 1b OpACIN trial of ipilimumab and nivolumab in patients with macroscopic stage III melanoma.

Heinz-Josef Lenz, MD, discusses the significance of conducting biomarker testing in patients with metastatic colorectal cancer in accordance with the results of the phase 2 CheckMate-142 trial.

Richard R. Furman, MD, discusses the distinguishing features between the 3 different Bruton’s tyrosine kinase inhibitors as treatment of patients with B-cell malignancies.

Jeff Sharman, MD, reviews a case of a 79-year-old man with relapsed chronic lymphocytic leukemia.

Naval G. Daver, MD, discusses a phase 1b trial evaluating the efficacy of margolimab and azacitidine combination for patients with acute myeloid leukemia.

Hearn Jay Cho, MD, PhD, discusses the goals of the CureCloud study, an historic initiative of the Multiple Myeloma Research Foundation (MMRF), a leader in the acceleration of efforts to provide precisely the right treatment for each and every patient.

Yu Sunakawa, MD, PhD, discusses the data observed in the DELIVER trial, which was presented as an updated analysis of nivolumab in patients with advanced gastric cancer at the European Society of Oncology World Congress on Gastrointestinal Cancer 2020.